Aiming to streamline the compensation process for people claiming harm from COVID-19 vaccines, Robert F. | Aiming to ...

The CARDIO-TTRansform study did not meet its primary endpoint, which centered on reducing cardiovascular deaths or recurrent ...

In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for the prevention of both episodic and chronic migraines. While AbbVie’s market ...

When launching a drug as big as semaglutide, even as a generic, the market expectations are immense, and any fumble on the ...

Unexpectedly catapulted into global fame as a COVID-19 vaccine maker, BioNTech is on the verge of returning to its oncology ...

Lundbeck’s online promotion of migraine med Vyepti has caught the attention of the FDA, with the agency inking an untitled letter that calls out the company for potentially misleading efficacy claims.

The comment-seeking period and probe tie back to Sanofi’s marketing for its flu shot for adults ages 60 and over, which is ...

AbbVie’s Allergan Aesthetics, looking to open doors for the next generation of female leaders, welcomed a cohort of young ...

The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex ...

Following a major push by the industry’s heavyweights to simplify their businesses in recent years, Tanabe Pharma is | While ...

After pledging earlier this year to bolster its drug substance capabilities in Central Europe, German chemical company Evonik is turning its attention to the U.S. The company is laying out $100 ...

When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...